Prior Authorization Criteria: Cibinqo (abrocitinib) for Atopic Dermatitis
Customize your policy alerts
Sign up for all West Virginia Bureau for Medical Services (Department of Human Services) policy alerts
Know when West Virginia Bureau for Medical Services (Department of Human Services) releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria and approval rules for Cibinqo (abrocitinib) to treat adults with moderate-to-severe atopic dermatitis for West Virginia Bureau for Medical Services members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Cibinqo (abrocitinib)
Initial Therapy
Covered when ALL of the following are met:
Initial approval duration: 3 months.
Continuation Therapy / Reauthorization
Reauthorization covered when ALL of the following are met:
Continuation of therapy will be granted for 12 months.
Use of Cibinqo (abrocitinib) under this policy is limited to the FDA‑indicated population as described in the product labeling — specifically, adults. This policy applies when the prescriber documents that the patient meets the age and other labeling requirements for Cibinqo.
Key Coding and Thresholds
Provider Requirements, Step Therapy, and Denial Triggers
Prior authorization required; prescriber qualifications
Prior authorization is required for Cibinqo (abrocitinib). Approval requires prescription by an M.D./D.O. or a specialty-trained prescriber with a clinical specialty certification/degree in allergy, immunology, or dermatology, and meeting the listed clinical criteria.
Step therapy: two 30-day agent trials required
Patient must have failed a minimum 30-day trial of two agents from the specified list within the last 12 months. Required agents include a medium-to-high potency topical corticosteroid*, Elidel, Eucrisa, or tacrolimus; the topical steroid trial is required unless affected areas are sensitive, but two other agents from the list are still required.
- Each prior agent trial must be at least 30 days.
- Two separate agents must have been tried and failed within the past 12 months.
- If the affected area involves sensitive sites (face, folds, genitals), the medium-to-high potency topical steroid trial may be exempted, but two other agents from the list are still required.
Required documentation for initial and continuation requests
Prescriber must document the diagnosis of moderate-to-severe atopic dermatitis and include objective measures of extent and severity for both initial requests and reauthorization.
- Documented diagnosis of moderate-to-severe atopic dermatitis.
- Affected body surface area (BSA) and current affected BSA for reauthorization.
- Areas of involvement (e.g., face, folds, genitals) and symptom severity.
- History of prior therapies and dates/durations demonstrating the required 30-day trials of two agents in the last 12 months.
- For reauthorization: demonstrated continued compliance and documentation of satisfactory patient response.
Denial risks: missing documentation or unmet thresholds
Requests may be denied if the required documentation or prior therapy trials are not provided or if objective criteria are not met.
- Affected BSA less than 10% (BSA < 10%) fails the policy threshold and may trigger denial.
- Missing documentation of two minimum 30-day trials of specified agents within the past 12 months.
- Absence of prescriber qualification (not an M.D./D.O. or specialty-trained prescriber in allergy, immunology, or dermatology) or missing documentation of diagnosis and symptom severity.
Definitions
Background
Cibinqo (abrocitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with refractory, moderate‑to‑severe atopic dermatitis whose disease is not adequately controlled with other systemic therapies or when use of those therapies is inadvisable. Under this policy, approval requires documented moderate‑to‑severe disease (including affected body surface area and symptom severity) and prior therapy trials per the coverage criteria.
Revision History
Policy effective date published for Cibinqo (abrocitinib) prior authorization criteria by West Virginia Bureau for Medical Services.
Established coverage criteria including required prescriber specialty, documented moderate-to-severe atopic dermatitis with BSA ≥10%, and failure of two 30‑day trials of specified agents prior to approval; initial approval duration set to 3 months.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.